CANCER LETTERS

Scope & Guideline

Elevating the discourse in cancer science.

Introduction

Explore the comprehensive scope of CANCER LETTERS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore CANCER LETTERS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0304-3835
PublisherELSEVIER IRELAND LTD
Support Open AccessNo
CountryIreland
TypeJournal
Convergefrom 1975 to 2024
AbbreviationCANCER LETT / Cancer Lett.
Frequency28 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE 00000, IRELAND

Aims and Scopes

Cancer Letters is a leading journal that focuses on the dissemination of significant research findings in all areas of cancer research, including molecular biology, therapeutic strategies, and clinical applications. The journal emphasizes innovative approaches to understanding cancer biology and improving cancer treatment outcomes.
  1. Molecular Mechanisms of Cancer:
    Research articles often explore the molecular and cellular mechanisms underlying cancer development and progression, including genetic, epigenetic, and metabolic alterations.
  2. Therapeutic Strategies:
    The journal publishes studies on novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments aimed at improving patient outcomes.
  3. Tumor Microenvironment:
    A significant focus is placed on the interactions between cancer cells and their microenvironment, including the roles of stromal cells, immune cells, and extracellular vesicles.
  4. Clinical Research and Trials:
    Cancer Letters includes articles detailing clinical trials and studies that aim to translate laboratory findings into effective treatments for cancer patients.
  5. Emerging Technologies:
    The journal highlights the use of advanced technologies, such as single-cell sequencing and CRISPR, to investigate cancer biology and develop new therapeutic strategies.
In recent years, Cancer Letters has seen a rise in research themes that reflect contemporary challenges and advancements in cancer biology and treatment. These emerging scopes indicate a shift toward more innovative and integrated approaches to cancer research.
  1. Immunotherapy and Immune Checkpoint Inhibition:
    A significant increase in publications focusing on immunotherapy, particularly immune checkpoint inhibitors, reflects the growing importance of harnessing the immune system to combat cancer.
  2. Targeted Therapies and Precision Medicine:
    Research on targeted therapies that consider individual patient genetic profiles is trending, showcasing a movement towards personalized cancer treatment.
  3. Metabolism and Cancer:
    The exploration of metabolic pathways in cancer cells and their influence on tumor progression and treatment resistance is gaining momentum.
  4. Extracellular Vesicles and Cell-Cell Communication:
    There is a rising interest in the role of extracellular vesicles in cancer biology, particularly regarding their role in intercellular communication and tumor microenvironment modulation.
  5. Cancer Stem Cells and Tumor Heterogeneity:
    Studies investigating cancer stem cells and tumor heterogeneity are increasingly prominent, emphasizing the complexity of tumor biology and the need for novel therapeutic strategies.

Declining or Waning

While Cancer Letters remains at the forefront of cancer research, certain areas of focus appear to be declining over the recent publication years. These waning themes reflect shifting interests in the oncology research community.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decline in articles solely focused on traditional chemotherapy regimens, as research increasingly shifts towards personalized medicine and targeted therapies.
  2. Basic Epidemiological Studies:
    The publication of basic epidemiological studies related to cancer incidence and prevalence has decreased, as more researchers are focusing on molecular and mechanistic insights.
  3. Single Modality Treatment Approaches:
    Research that emphasizes single modality treatments (e.g., surgery or radiation alone) is becoming less common, with a growing interest in combination therapies that include immunotherapy and targeted agents.
  4. Static Models of Cancer Research:
    There is a reduced emphasis on static models of cancer that do not account for the dynamic nature of tumor biology and the tumor microenvironment.
  5. Generalized Biomarker Studies:
    Studies focusing on generalized biomarkers without specific context or mechanistic insights are becoming less frequent, as researchers seek more precise and actionable biomarker identification.

Similar Journals

BRITISH JOURNAL OF CANCER

Connecting Researchers and Clinicians in the Fight Against Cancer.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Transforming Cancer Knowledge into Impactful Solutions
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

MOLECULAR CANCER THERAPEUTICS

Pioneering discoveries for a cancer-free tomorrow.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

INTERNATIONAL JOURNAL OF CANCER

Shaping the future of oncology through rigorous research.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Oncologie

Transforming cancer treatment through rigorous research.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Frontiers in Oncology

Leading the charge in transformative oncology research.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Cancer Reports

Bridging gaps in cancer care with cutting-edge research.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Cancer Biomarkers

Pioneering Research in Oncology and Genetics.
Publisher: IOS PRESSISSN: 1574-0153Frequency: 12 issues/year

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Molecular and Clinical Oncology

Empowering breakthroughs in cancer biology and treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Molecular Oncology

Unlocking Innovations in Molecular Medicine.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.